Jurisdictional Skepticism Puts Eli Lilly Appeal On Thin Ice
Eli Lilly & Co.'s bid to unwind the U.S. Food and Drug Administration's refusal to classify a developing obesity treatment as a biological product appears to suffer from jurisdictional issues that...To view the full article, register now.
Already a subscriber? Click here to view full article